Cambridge, United Kingdom · Founded 2013 · Privately Held (backing)
Developer of a protein prototyping system designed to accelerate drug discovery workflows. Nuclera is based in Cambridge, United Kingdom and was founded in 2013. It was valued at $155 million at its Series B in Jul 2022, the last priced event on record. It has raised $166 million across 9 recorded rounds; the latest was an $87 million Series C in Jan 2026.
PMV mark · valuation
$154.5M
Oct 2026
Priced at
its Series B
Jul 2022
Total raised
$166.1M
Last round
Later Stage VC (Series C)
Jan 2026
No prints on record
No secondary trades in Nuclera shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Nuclera with a free account
·Post-money valuations for 2 rounds
·The complete investor list: 22 names
·Watch Nuclera: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Nuclera stock.
